QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Follow-Up Questions
Qiagen NV (QGEN) 的本益比是多少?
Qiagen NV 的本益比是 118.3673
Qiagen NV 的 CEO 是誰?
Mr. Thierry Bernard 是 Qiagen NV 的 Chief Executive Officer,自 2020 加入公司。
QGEN 股票的價格表現如何?
QGEN 的當前價格為 $45.36,在上個交易日 decreased 了 0.81%。
Qiagen NV 的主要業務主題或行業是什麼?
Qiagen NV 屬於 Life Sciences Tools & Services 行業,該板塊是 Health Care